Skip to main content

Table 3 AUC improvements relative to placebo

From: Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis

Assessment

Parameter

PBO

MEM

PBO-DON

MEM-DON

 

number = 281

number = 289

number = 418

number = 429

SIB

AUC0-24 a

−51.4 ± 10.9

4.9 ± 10.5

27.5 ± 8.6

67.4 ± 8.3

│Xb - PBO│c

0

56.3*

78.9***

118.8***

│Xb - PBO│/│PBO│, %

-

109.6

153.5

231.1

ADCS-ADL19

AUC0-24 a

−32.7 ± 6.4

−12.2 ± 6.2

−9.5 ± 5.0

1.4 ± 4.9

│Xb - PBO│c

0

20.5

23.3*

34.2***

│Xb - PBO│/│PBO│, %

-

62.6

71.1

104.4

NPId

AUC0-24 a

22.4 ± 12.2

−7.3 ± 11.8

−27.2 ± 9.7

−74.3 ± 9.4

│Xb - PBO│c

0

29.8

49.6**

96.8***

│Xb - PBO│/│PBO│, %

-

132.5

221.0

431.2

CIBIC-Plus

AUC0-24 a

6.0 ± 1.1

2.0 ± 1.0

1.4 ± 0.9

−2.1 ± 0.8

│Xb - PBO│c

0

4.0

4.6*

8.1***

│Xb - PBO│/│PBO│, %

-

65.9

76.2

135.6

4D-CI

AUC0-24 a

−175.4 ± 63.7

152.1 ± 61.5

344.7 ± 50.4

630.0 ± 49.0

│Xb - PBO│c

0

327.4**

520.0***

805.4***

│Xb - PBO│/│PBO│, %

-

186.7

296.6

459.3

  1. aMean ± SE (point x week); bany active treatment group; cmean (point x week); dfor NPI, lower score indicates improvement. *P <0.05; **P <0.01; ***P <0.001. 4D-CI, four-dimensional composite index; ADCS-ADL19, 19-item Alzheimer’s Disease Cooperative Study – Activities of Daily Living scale; AUC, area under the curve; CIBIC-Plus, Clinician’s Interview-Based Impression of Change – Plus Caregiver Input; MEM, memantine; MEM-DON, memantine added to background donepezil treatment; NPI, Neuropsychiatric Inventory; PBO, placebo; PBO-DON, placebo added to background donepezil treatment; SE, standard error of the mean; SIB, Severe Impairment Battery.